Apogee Therapeutics (APGE) Liabilities and Shareholders Equity (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Liabilities and Shareholders Equity data on file, last reported at $1.3 billion in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 81.14% year-over-year to $1.3 billion in Q1 2026; TTM through Mar 2026 was $3.5 billion, a 15.42% increase from a year earlier, with the FY2025 full-year figure at $937.1 million, up 24.3% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.3 billion, up from $937.1 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for APGE reached as high as $1.3 billion in Q1 2026 and fell as low as $130.7 million in Q2 2023.
• Historically, Liabilities and Shareholders Equity has averaged $653.4 million across 5 years, with a median of $714.2 million in 2025.
• Across the five-year window, Liabilities and Shareholders Equity jumped 512.75% in 2024 and fell 19.34% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $152.1 million in 2022, then surged by 163.99% to $401.4 million in 2023, then surged by 87.83% to $754.0 million in 2024, then grew by 24.3% to $937.1 million in 2025, then jumped by 38.04% to $1.3 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $1.3 billion in Q1 2026, $937.1 million in Q4 2025, and $626.2 million in Q3 2025.